Kidney Transplant Rejection Pipeline Grows as 10+ Pharma Companies Advance Novel Immunotherapies, Finds DelveInsight | Biogen, Eledon Pharmaceuticals, Medeor Therapeutics, Sangamo Therapeutics, Sanofi

DelveInsight's "Kidney Transplant Rejection - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies developing several pipeline drugs in the Kidney Transplant Rejection pipeline landscape. It covers the Kidney Transplant Rejection pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Kidney Transplant Rejection treatment landscape. Learn more about the evolving Kidney Transplant Rejection pipeline today @ https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Kidney Transplant Rejection Pipeline Report

• In April 2026, Medeor Therapeutics reported that its innovative cell therapy MDR-101 is advancing through Phase III clinical trials, with an anticipated launch in the US market by 2026 for the prevention of kidney transplant rejection.
• In January 2026, market forecasts indicate the Kidney Transplant Rejection market in the 7MM is expected to reach USD 4,260 million by 2025, driven by the increasing prevalence of End-stage Renal Disease (ESRD) and a growing number of incident transplant cases.
• In November 2025, research highlighted that high-throughput cellular and molecular biotechnologies are facilitating the identification of new non-invasive biomarkers, such as dd-cfDNA, which offer prognostic insight and earlier detection of graft injury.
• Kidney transplant rejection remains a significant clinical challenge, with approximately 10-20% of recipients experiencing acute rejection and up to 50% of grafts failing within 10 years, necessitating advanced systemic immunotherapies.
• DelveInsight's Kidney Transplant Rejection Pipeline Insight report depicts a robust clinical development space with over 10 active players advancing 12+ pipeline therapies across multiple stages, from discovery through Phase III.
• Biogen holds a leading Phase III candidate, Felzartamab, a monoclonal antibody targeting CD38-expressing cells specifically designed to address antibody-mediated rejection (ABMR).
• Eledon Pharmaceuticals is advancing Tegoprubart (AT-1501), an engineered anti-CD40L monoclonal antibody currently in Phase II clinical evaluation, aiming to improve immunosuppression safety and minimize thromboembolic risks.
• The leading Kidney Transplant Rejection companies include Biogen, Eledon Pharmaceuticals, Medeor Therapeutics, Sangamo Therapeutics, Sanofi, TRACT Therapeutics, and others.
• Promising Kidney Transplant Rejection therapies in development include Felzartamab, Tegoprubart, TX200 (a CAR-Treg cell therapy), and other clinical-stage candidates spanning monoclonal antibodies and cell therapies.

Download for updates and the latest revolution in Kidney Transplant Rejection care @ https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Kidney Transplant Rejection Emerging Drugs Profile

• Felzartamab: Biogen
Felzartamab is an investigational human monoclonal antibody that targets CD38, a protein highly expressed on plasma cells and certain immune cells involved in antibody-mediated rejection (ABMR). By depleting these CD38-positive cells, Felzartamab aims to reduce the production of donor-specific antibodies that attack the transplanted kidney. Currently, Felzartamab is in Phase III clinical evaluation for the treatment of Kidney Transplant Rejection, specifically focusing on patients with chronic active ABMR.

• Tegoprubart (AT-1501): Eledon Pharmaceuticals
Tegoprubart is an engineered humanized monoclonal antibody designed to target and inhibit the CD40L (CD154) costimulatory pathway. This pathway is critical for the activation of T cells and their interaction with other immune cells during the rejection process. Tegoprubart has been engineered to eliminate Fc-mediated effector function, thereby reducing the risk of thromboembolic complications associated with earlier anti-CD40L candidates. Currently, it is in Phase II clinical trial evaluation for the prevention of organ rejection in kidney transplant recipients.

• TX200: Sangamo Therapeutics
TX200 is a first-in-class CAR-Treg cell therapy composed of autologous regulatory T cells (Tregs) engineered to express an HLA-A2 chimeric antigen receptor (CAR). The therapy is designed to accumulate specifically in the transplanted kidney where the HLA-A2 protein is present, promoting local immune tolerance and potentially reducing the lifelong dependence on non-specific immunosuppressive medications. Currently, TX200 is in Phase I/II clinical trial evaluation for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

For more information on the Kidney Transplant Rejection Emerging Drugs Profile, download DelveInsight's comprehensive Kidney Transplant Rejection Pipeline Insight report @ https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Kidney Transplant Rejection Pipeline Report Provides

• Detailed insights about companies developing therapies for Kidney Transplant Rejection, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Kidney Transplant Rejection treatment.
• Kidney Transplant Rejection companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Kidney Transplant Rejection drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Kidney Transplant Rejection market.

Learn more about Kidney Transplant Rejection drug opportunities in our comprehensive Kidney Transplant Rejection pipeline report @ https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Kidney Transplant Rejection Companies and Competitive Landscape

There are 10+ key companies, including Biogen, Eledon Pharmaceuticals, Medeor Therapeutics, Sangamo Therapeutics, Sanofi, TRACT Therapeutics, and others, developing therapies for Kidney Transplant Rejection, with Medeor Therapeutics and Biogen having their drug candidates in the most advanced Phase III stage.

DelveInsight's Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Kidney Transplant Rejection products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Kidney Transplant Rejection treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Kidney Transplant Rejection Pipeline Report

• Coverage: Global
• Kidney Transplant Rejection Companies: Biogen, Eledon Pharmaceuticals, Medeor Therapeutics, Sangamo Therapeutics, Sanofi, TRACT Therapeutics, and others.
• Kidney Transplant Rejection Therapies: Felzartamab, Tegoprubart (AT-1501), TX200, MDR-101, and other pipeline candidates.
• Kidney Transplant Rejection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Kidney Transplant Rejection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.